Science of the cell cycle by De Bruin, RAM
Can you elaborate on how your research 
interests have evolved throughout your 
early postdoctoral work? 
Throughout my career, my work has 
concentrated on the importance of 
transcriptional control during development, 
the cell division cycle, and its response to 
internal and environmental signals. During 
my postdoctoral work at the Scripps Research 
Institute in California, USA, I started to focus 
on the mechanisms involved in transcriptional 
regulation during the gap phase-1 and 
synthesis phase (G1 and S phases). 
In 2009, I joined the Laboratory for Molecular 
Cell Biology at University College London 
(UCL), UK, as an independent group leader. 
Since then, cell cycle-regulated transcription 
has remained my main focus. Studies from 
my lab have led to the discovery of a simple 
yet elegant mechanism by which the DNA 
replication checkpoint can override the 
G1/S transcriptional programme by directly 
regulating the transcriptional repressor in 
both yeast and human cells. Overall, our 
discoveries have revealed that regulatory 
mechanisms are conserved in evolutionarily 
diverged systems.
Why is your research focused on the G1- 
and S-phases of the cell cycle? Can you 
brieﬂ y outline what these involve and how 
they ﬁ t into the cycle as a whole? 
Cell division is a process essential to the 
propagation of life. At the heart of controlling 
cell proliferation lies the transition from the 
G1-phase of the cell cycle to the S-phase, 
when the cell ‘decides’ whether or not to 
enter a new division cycle and undergo 
DNA replication. This decision coincides 
with the activation of G1/S transcription, 
which comprises a large number of dosage-
sensitive co-regulated genes that encode 
proteins involved in many essential cellular 
functions, such as cell division control, DNA 
replication, cell growth and maintenance of 
genome stability. 
Importantly, the most commonly 
deregulated transcriptional networks in 
cancers are active during the G1- and 
S-phases of the cell cycle. These include 
G1/S transcription and the transcriptional 
response to DNA replication stress during 
S-phase, which are both foci of our current 
work. Our investigations aim to provide 
unique insight into the role of these 
transcriptional networks in both healthy 
cells and pathological conditions.
For what reason have you chosen yeast as 
a model species? 
Parallel work in fi ssion yeast, 
Schizosaccharomyces pombe, and 
the distantly related budding yeast, 
Saccharomyces cerevisiae, has allowed 
us to make important discoveries in 
human cells, which serve as a model 
for human disease. Our experimental 
setup allows us to translate the insights 
obtained in yeast directly into the more 
complex human system, based on either 
sequence or functional conservation of the 
proteins involved.
What hopes do you have for the 
translational potential of your work? 
I have high hopes that our current work will 
lead to new insights into human cancer and 
provide novel therapeutic approaches that 
will translate into benefi ts for patients and 
their families. Cancer-associated mutations 
that drive dysfunctional S-phase entry 
cause high levels of replication stress, and 
the cellular response to this is therefore 
thought to be particularly important 
for certain cancer cells. Consequently, 
targeting proteins with an essential role in 
the response to replication stress creates 
a potentially large therapeutic window for 
damaging cancer cells without affecting 
normal cells. 
Futhermore, our future work will provide a 
detailed understanding of how individual 
G1/S targets shape the outcome of 
replication stress-induced events, such 
as cell survival and genome stability. 
It is therefore expected to help exploit 
vulnerabilities of cancer cells with high levels 
of replication stress and guide us towards 
more effective strategies for cancer therapy.
Much of your work involves fundamental 
science. How does the importance of this 
compare to more translational research?
While we aim to directly translate the 
insights obtained in yeast to humans, we 
are continuing to build on our fi ndings 
in yeast. This work is more fundamental 
and it is therefore less obvious how it 
will translate into signifi cant benefi ts for 
patients. However, if the past has shown us 
anything it is that this type of fundamental 
work is essential for making new discoveries 
that form the basis of translational research 
in subsequent years. Therefore, it is of the 
utmost importance to keep funding and 
carrying out basic research to drive research 
discoveries that will benefi t patients in 
the future. 
Dr Rob de Bruin describes his research on cell cycle-regulated transcription and explains how it may 
ultimately contribute to a better understanding of cancer and the development of novel therapeutics
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Not just a phase
A group of researchers from the Laboratory for Molecular Cell Biology at University College London is 
investigating the fundamental biological mechanisms that impact cell cycle progression and genomic stability
DEFECTS IN THE regulation of the gap 
phase-1 and synthesis phase (G1 and S phases) 
genes can be detected in every cancer type. The 
regulation of these genes, collectively known 
as G1/S transcripts, plays a central role in the 
cell cycle – the process whereby healthy cells 
divide and multiply in a regulated manner. 
Cancer is, by definition, a disease in which cells 
multiply uncontrollably; therefore the presence 
of deregulated G1/S transcription in cancerous 
cells implies that it is an abnormality of the cell 
cycle regulation pathway that paves the way 
for tumourigenesis. 
This aspect of cell biology is the focus of Dr Rob 
de Bruin’s research group. Based in the Laboratory 
for Molecular Cell Biology at University College 
London (UCL), UK, his team conducts both 
molecular and biochemical experiments, using 
two species of yeast – Saccharomyces cerevisiae 
and Schizosaccharomyces pombe – and human 
cell lines as models of cancer, to elucidate the 
processes by which changes in gene expression 
impact cell cycle control and genome stability in 
both healthy and pathogenic cells.
OUT OF CONTROL 
De Bruin’s interest in G1/S transcription 
activation began early in his career while 
conducing postdoctoral research at the Scripps 
Research Institute in California, USA. Using 
yeast models, de Bruin successfully identified 
Whi5 as a transcriptional repressor involved in 
G1/S transcriptional regulation, and revealed 
that it was analogous to the retinoblastoma 
(pRb) tumour suppressor in mammals. He also 
identified a negative feedback loop in yeast cells 
that turns off G1/S transcription during S-phase 
cycle activity.
Upon joining UCL in 2009, de Bruin was able to 
establish his own research group using funds from 
a Medical Research Council Career Development 
Award. Here, he has continued to investigate 
G1/S transcription, with the ultimate aim of 
furthering understanding of cancer pathogenesis. 
Already, the group has: demonstrated that the 
previously identified negative loop turns off 
G1/S transcription during S-phase in human 
cells as well as yeast; established a mechanism 
by which the DNA-replication checkpoint can 
override the G1/S transcription programme by 
directly regulating the transcriptional repressor; 
and identified different subgroups of G1/S 
targets that are regulated by distinct molecular 
mechanisms in budding yeast. 
At present, the team is focusing on identifying 
the cellular functions that cancer cells 
specifically depend on as a result of deregulated 
G1/S transcription. By exploring the various 
mechanisms at play in yeast models and 
human cell lines, they hope to develop a deeper 
understanding of the factors that impact 
tumour development.
REPLICATION STRESS
In addition, de Bruin’s team is investigating 
transcriptional responses to DNA replication 
stress during the S-phase of the cell cycle. 
Replication stress (where insufficient DNA 
replication occurs, causing DNA replication forks 
to progress slowly or stop) can occur as a result 
of a number of factors, including deregulation 
of components required for DNA synthesis or 
a problem with the frequency of replication 
initiation. “The ability of cells to cope with such 
genotoxic stress is largely dependent on the 
action of the DNA replication checkpoint – an 
evolutionarily conserved signalling pathway that 
constantly monitors for the loss of integrity at 
the DNA replication fork,” explains de Bruin. 
Again, the researchers are exploring these 
cellular functions through the use of yeast and 
human cell lines.
Particular attention is being paid to the Nrm1 
transcriptional repressor. De Bruin and his 
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OBJECTIVES
This research addresses three fundamental 
questions related to G1/S transcription: 
• What is the role of G1/S cell-cycle 
transcription in the cellular response to 
replication stress? 
• How does deregulated G1/S transcription 
contribute to genomic instability and the 
dependency on particular pathways for 
cell survival? 
• How do chromatin-modifying enzymes 
control gene expression during the G1 and 
S-phases of the cell-cycle?
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ROB DE BRUIN is Group Leader in the MRC 
Laboratory for Molecular Cell Biology. Prior 
to this he was a postdoctoral fellow at the 
Scripps Research Institute, USA. He has 
been awarded an MRC Career Development 
award (2009) and the AAAS/Science 
Program for Excellence in Science (2007). 
De Bruin has 26 peer-reviewed publications 
and, in addition to his research, supervises a 
research assistant, postdoctoral researcher 
and three graduate students.
colleagues were the fi rst investigators to 
successfully delineate the essential role played 
by Nrm1 as a regulator of the cell cycle – it 
turns off G1/S transcription when exiting the 
G1-phase – and to establish its position as a 
target within the DNA replication checkpoint 
pathway. Building on these fi ndings, the 
researchers are now anxious to obtain a more 
complete understanding of the underlying 
mechanisms. To achieve this, they are pursuing 
several avenues of investigation: exploring 
the biological relevance of restricting gene 
expression during the G1-phase and the 
inﬂ uence of gene expression on checkpoint 
response; and studying how gene expression 
during the G1- and S-phases is regulated at the 
chromatin level.
Particular attention is being paid to the family 
of proteins known as the E2F transcription 
factors, which regulate G1/S transcription 
in human cells. “Our work has shown that 
maintaining E2F-dependent transcription is 
an essential part of the checkpoint response 
to prevent replication stress-induced DNA 
damage,” states de Bruin. Gene expression, 
regulated by E2F transcription factors, plays a 
crucial role in the human cell stress response; 
replication stress as a result of a failure to 
maintain E2F-dependent transcription can lead 
to irreparable DNA damage and cell death. For 
this reason, the team is studying the ways in 
which E2F target genes can shape the outcome 
of replication stress in terms of cell survival and 
genome stability.
LITTLE MECHANISMS, LARGE IMPACT
By bringing to light the mechanisms through 
which cell cycles become deregulated and 
genomes unstable, this research is contributing 
to a wealth of basic and translational 
knowledge. Such information is not only vital 
for the identifi cation of novel anticancer drug 
targets and the development of new therapeutic 
approaches, it may also hold as yet unknown 
benefi ts for future generations. Given that 
genome instability and loss of transcriptional 
control are associated with ageing and 
over 60 inheritable diseases – ranging from 
neurodegenerative to autoimmune disorders 
and cancer – there is no telling what may 
one day be gained from the knowledge being 
gathered today.
INTERNATIONAL INNOVATION ASKS 
DR ROB DE BRUIN TO DISCUSS HIS 
CAREER HIGHS AND LOWS 
CAREER HIGHLIGHT: “My proudest academic 
achievement was as an undergraduate 
student, when I was involved in pioneering 
and fundamental research on transgene 
silencing in plants, carried out in the Mol 
laboratory in Amsterdam, The Netherlands. The 
experiment in which I was involved used some 
unconventional methods to demonstrate that 
effective post-transcriptional gene silencing 
required an inverted T-DNA repeat loci 
organisation – what is now known as a ‘hairpin 
structure’. This, and other work, eventually led 
to the development of RNA interference (RNAi) 
technology, which has been one of the most 
important new fi ndings in biology over the 
last decade.”
CAREER CHALLENGES: “The biggest diffi culty 
I’ve encountered in my career has been entering 
and establishing myself in new fi elds of research, 
transiting both from yeast to human cells and 
from G1/S transcription to the genome integrity 
checkpoint. While it is very exciting to take your 
research in new directions, you will always face 
resistance from people already established in 
those fi elds. The only way to overcome this 
diffi culty is to see it as a challenge and continue 
to do good science, which will eventually lead to 
becoming a member of a new club.”
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